Adaptive immunity to SARS-CoV-2 infection: A systematic review

Front Immunol. 2022 Oct 10:13:1001198. doi: 10.3389/fimmu.2022.1001198. eCollection 2022.

Abstract

Background: There is evidence that the adaptive or acquired immune system is one of the crucial variables in differentiating the course of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This work aimed to analyze the immunopathological aspects of adaptive immunity that are involved in the progression of this disease.

Methods: This is a systematic review based on articles that included experimental evidence from in vitro assays, cohort studies, reviews, cross-sectional and case-control studies from PubMed, SciELO, MEDLINE, and Lilacs databases in English, Portuguese, or Spanish between January 2020 and July 2022.

Results: Fifty-six articles were finalized for this review. CD4+ T cells were the most resolutive in the health-disease process compared with B cells and CD8+ T lymphocytes. The predominant subpopulations of T helper lymphocytes (Th) in critically ill patients are Th1, Th2, Th17 (without their main characteristics) and regulatory T cells (Treg), while in mild cases there is an influx of Th1, Th2, Th17 and follicular T helper cells (Tfh). These cells are responsible for the secretion of cytokines, including interleukin (IL) - 6, IL-4, IL-10, IL-7, IL-22, IL-21, IL-15, IL-1α, IL-23, IL-5, IL-13, IL-2, IL-17, tumor necrosis factor alpha (TNF-α), CXC motivating ligand (CXCL) 8, CXCL9 and tumor growth factor beta (TGF-β), with the abovementioned first 8 inflammatory mediators related to clinical benefits, while the others to a poor prognosis. Some CD8+ T lymphocyte markers are associated with the severity of the disease, such as human leukocyte antigen (HLA-DR) and programmed cell death protein 1 (PD-1). Among the antibodies produced by SARS-CoV-2, Immunoglobulin (Ig) A stood out due to its potent release associated with a more severe clinical form.

Conclusions: It is concluded that through this study it is possible to have a brief overview of the main immunological biomarkers and their function during SARS-CoV-2 infection in particular cell types. In critically ill individuals, adaptive immunity is varied, aberrantly compromised, and late. In particular, the T-cell response is also an essential and necessary component in immunological memory and therefore should be addressed in vaccine formulation strategies.

Keywords: COVID-19; SARS-CoV-2; adaptive immunity; humoral immunity; immunity.

Publication types

  • Systematic Review

MeSH terms

  • Adaptive Immunity
  • COVID-19*
  • Critical Illness
  • Cross-Sectional Studies
  • HLA-DR Antigens
  • Humans
  • Immunoglobulins
  • Inflammation Mediators
  • Interleukin-10
  • Interleukin-13
  • Interleukin-15
  • Interleukin-17
  • Interleukin-2
  • Interleukin-23
  • Interleukin-4
  • Interleukin-5
  • Interleukin-7
  • Ligands
  • Programmed Cell Death 1 Receptor
  • SARS-CoV-2
  • Transforming Growth Factor beta
  • Tumor Necrosis Factor-alpha

Substances

  • Programmed Cell Death 1 Receptor
  • Interleukin-10
  • Interleukin-15
  • Interleukin-17
  • Interleukin-13
  • Tumor Necrosis Factor-alpha
  • Ligands
  • Interleukin-2
  • Interleukin-4
  • Interleukin-5
  • Interleukin-7
  • HLA-DR Antigens
  • Interleukin-23
  • Inflammation Mediators
  • Transforming Growth Factor beta
  • Immunoglobulins